Insider Trading April 2, 2026

Cardlytics CLO Disposes $39,893 of Stock While Exercising RSUs

Lynton Hollmeyer sold 40,296 shares and concurrently acquired 85,590 shares via restricted stock unit exercise on April 1, 2026

By Marcus Reed CDLX
Cardlytics CLO Disposes $39,893 of Stock While Exercising RSUs
CDLX

Cardlytics Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer reported a sale of 40,296 shares of company stock on April 1, 2026, at a weighted average price of $0.99 for proceeds of $39,893, while on the same day exercising restricted stock units that resulted in the acquisition of 85,590 shares. The company recently posted mixed fourth-quarter fiscal 2025 results, completed an asset sale of its Bridg platform in exchange for PAR Technology common shares, and faced price-target cuts from analysts citing partner-related challenges.

Key Points

  • CLO Lynton Nicholas Hollmeyer sold 40,296 shares on April 1, 2026, at a weighted average price of $0.99 for total proceeds of $39,893; trade prices ranged from $0.965 to $1.040.
  • On the same day Hollmeyer exercised restricted stock units and acquired 85,590 shares of Cardlytics common stock.
  • Cardlytics reported Q4 fiscal 2025 revenue of $56.1 million, beating estimates by 1.69%, with EPS of -$0.28 in line with expectations; the company also received 1,810,222 shares of PAR Technology common stock in the sale of its Bridg platform.

Cardlytics, Inc. reported an insider transaction involving its Chief Legal & Privacy Officer, Lynton Nicholas Hollmeyer, who sold 40,296 shares of common stock on April 1, 2026. The sale carried a weighted average execution price of $0.99 per share, generating total proceeds of $39,893. The range of prices at which the shares traded that day was $0.965 to $1.040.

On the same date Hollmeyer also realized a separate equity event: the exercise of restricted stock units that resulted in the acquisition of 85,590 shares of Cardlytics common stock. Both transactions were disclosed on April 1, 2026.

InvestingPro analysis, as cited in company filings, indicates the stock appears undervalued at current levels. The firm notes that a comprehensive Pro Research Report on Cardlytics (CDLX) is available among more than 1,400 reports that the service offers for investors seeking detailed analysis.


Cardlytics’ recent operating results were mixed. For the fourth quarter of fiscal 2025 the company reported revenue of $56.1 million, topping expectations of $55.17 million by 1.69%. Earnings per share were a loss of $0.28, which matched analyst projections.

Separately, Cardlytics completed the divestiture of its Bridg platform assets to PAR Technology Corporation. As consideration, Cardlytics received 1,810,222 shares of PAR Technology common stock as part of the transaction.


On the analyst front, Evercore ISI adjusted its price target for Cardlytics down to $1 from $2 while maintaining an In Line rating. The firm attributed the change in part to the end of Cardlytics’ partnership with Bank of America and ongoing content restrictions at Chase that impacted the company’s first-quarter outlook. BofA Securities also lowered its price target, moving it to $0.90 from $1.50 and citing developments with two major financial institution partners as a reason for the cut.

These analyst revisions underscore the challenges Cardlytics is facing as it manages partner relationships and investor expectations. The company’s insider activity, recent financial results, and the Bridg asset sale together present a multifaceted picture of its near-term position.

Risks

  • Partnership disruptions - The end of the Bank of America partnership and content restrictions at Chase have been cited by analysts as factors weakening Cardlytics’ outlook, affecting the financial services sector.
  • Analyst downgrades and lower price targets - Evercore ISI and BofA Securities reduced price targets for Cardlytics, reflecting uncertainty in the company’s near-term revenue and investor sentiment in the fintech and advertising technology markets.
  • Stock volatility tied to insider transactions and asset sales - The combination of insider selling, RSU exercises, and the receipt of a large block of PAR Technology shares as consideration for the Bridg sale may contribute to trading volatility in Cardlytics stock and related securities.

More from Insider Trading

National CineMedia General Counsel Sells $36,680 in NCMI Stock Amid Recent Vesting Apr 2, 2026 Adaptive Biotechnologies COO Sells $553,693 in ADPT Stock as Options Are Exercised; Adeptus Posts Q4 Beat Apr 2, 2026 Zenas BioPharma Director Buys $70,197 in Stock as Company Advances Clinical and Financing Plans Apr 2, 2026 Accel Entertainment CEO Disposes of $497K in Stock as Company Posts Strong Q4 Results Apr 2, 2026 Axcelis CEO Executes $117K Sale; Company Posts Strong Quarter Amid Leadership Moves Apr 2, 2026